APA (7th ed.) Citation

A, M., M, J., RL, M., C, L., B, M., S, S., . . . T, S. (2022). Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): Multicentre, double-blind, placebo-controlled, phase 3 trial. The Lancet. Respiratory medicine, 10(2), 158. https://doi.org/10.1016/S2213-2600(21)00440-9

Chicago Style (17th ed.) Citation

A, Mazeraud, et al. "Intravenous Immunoglobulins in Patients with COVID-19-associated Moderate-to-severe Acute Respiratory Distress Syndrome (ICAR): Multicentre, Double-blind, Placebo-controlled, Phase 3 Trial." The Lancet. Respiratory Medicine 10, no. 2 (2022): 158. https://doi.org/10.1016/S2213-2600(21)00440-9.

MLA (9th ed.) Citation

A, Mazeraud, et al. "Intravenous Immunoglobulins in Patients with COVID-19-associated Moderate-to-severe Acute Respiratory Distress Syndrome (ICAR): Multicentre, Double-blind, Placebo-controlled, Phase 3 Trial." The Lancet. Respiratory Medicine, vol. 10, no. 2, 2022, p. 158, https://doi.org/10.1016/S2213-2600(21)00440-9.